A takeover rumor regarding Akero Therapeutics (AKRO) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly. Akero shares are up 93c, or 2%, to $55.21 in early Monday trading.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics Elects New Directors at Annual Meeting
- Buy Rating for Akero Therapeutics Driven by EFX’s Promising Position in MASH Treatment and Market Potential
- 3 Best Stocks to Buy Now, 5/27/2025, According to Top Analysts
- Akero Therapeutics price target raised to $64 from $63 at BofA
- Biotech Alert: Searches spiking for these stocks today
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue